Back to Search
SAFWAN HALABI, MD
MD
Diagnostic Radiology Physician
NPI: 1669491320Individual
Specialties, Licenses & Credentials
Pediatric Radiology Physician
Radiology — Pediatric Radiology
Code: 2085P0229X
DR.0048768(CO)87714(OH)036119690(IL)
Diagnostic Radiology PhysicianPrimary
Radiology — Diagnostic Radiology
Code: 2085R0202X
0433604(KS)4301078558(MI)2009002511(MO)A105003(CA)036119690(IL)
Diagnostic Ultrasound Physician
Radiology — Diagnostic Ultrasound
Code: 2085U0001X
036119690(IL)
Research & Publications (20)
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.
PMID 19633053·Ann Oncol·2010
8-other
The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.
PMID 19589569·Urology·2010
8-other
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.
PMID 18574490·Prostate Cancer Prostatic Dis·2009
8-other
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.
PMID 19380448·J Clin Oncol·2009
8-other
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.
PMID 19168670·Ann Oncol·2009
3-trial
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
PMID 19211452·J Natl Cancer Inst·2009
1-meta
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup.
PMID 18349276·Cancer Epidemiol Biomarkers Prev·2008
8-other
Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
PMID 18407435·Int J Radiat Oncol Biol Phys·2008
3-trial
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.
PMID 18487572·J Clin Oncol·2008
4-observational
Circulating levels of inflammatory cytokines and risk of colorectal adenomas.
PMID 18172326·Cancer Res·2008
8-other
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
PMID 18824434·Clin Genitourin Cancer·2008
3-trial
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
PMID 18291508·Urology·2008
3-trial
Second-line chemotherapy for advanced hormone-refractory prostate cancer.
PMID 18347563·Clin Adv Hematol Oncol·2008
6-review
Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women.
PMID 18303003·Am J Epidemiol·2008
8-other
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
PMID 18309951·J Clin Oncol·2008
6-review
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
PMID 18936475·J Clin Oncol·2008
3-trial
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
PMID 18272914·Ann Oncol·2008
3-trial
Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans.
PMID 18945689·Am J Epidemiol·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 4 locations total
- Address
- 13123 E 16TH AVE
AURORA, CO 80045 - Phone
- (720) 777-1234
Quick Facts
- NPI
- 1669491320
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 9
- Locations
- 4
- Publications
- 20
Are you this provider?
Claim Your Profile